ArticleOcular oncology and pathology2020
Dabrafenib and Trametinib for BRAF-Mutated Conjunctival Melanoma.
Article in Ocular oncology and pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Imaging of Ocular Surface Lesions Using Anterior Segment Optical Coherence Tomography.Clinical & experimental ophthalmology · 2026Review
- [New systemic treatment approaches for conjunctival melanoma].Die Ophthalmologie · 2025Review
- Emerging Techniques in the Treatment of Conjunctival Melanoma.Current ophthalmology reports · 2025Review
- Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches.Pathology oncology research : POR · 2025Review
- Conjunctival Melanoma: A Clinical Review and Update.Cancers · 2024Review
- Advances in conjunctival melanoma: clinical features, diagnostic modalities, staging, genetic markers, and management.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2024Review
- Review
- BRAF and NRAS prognostic values in conjunctival melanoma: analysis and literature review.Arquivos brasileiros de oftalmologia · 2023Article
- Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening.Cancers · 2022Article
- Review
- Current Management of Conjunctival Melanoma Part 2: Treatment and Future Directions.Turkish journal of ophthalmology · 2020Review
- Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know.International journal of molecular sciences · 2020Review
- Current findings of genetic alterations and associated targeted therapies of conjunctival melanocytic neoplasms.Taiwan journal of ophthalmologyReview
- Personalized treatment concepts in extraocular cancer.Advances in ophthalmology practice and researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundConjunctival melanoma is a potentially lethal malignancy of the ocular surface. There have been no therapeutic advancements made in the past several decades despite increasing prevalence of the disease.
methodsThe authors report the case of a 52-year-old Caucasian male with unresectable, recurrent conjunctival melanoma with V600
resultsThere was complete regression of local disease within the first 9 months. The patient remains without local recurrence or systemic metastasis at 1 year.
conclusionThis is the first reported case of conjunctival melanoma with complete response to BRAF/MEK inhibition. As long as targeted therapy remains an option, patients with conjunctival melanoma should undergo mutational profiling of their tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.